Last updated on May 2019

Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC)


Brief description of study

National multicentric phase II trial evaluating whether single agent cetuximab is effective as maintenance therapy after 8 cycles of first line FOLFIRI plus cetuximab in mCRC patients with KRAS and NRAS wild-type genes, assessed by progression-free survival at 6 months after start of maintenance therapy.

Clinical Study Identifier: NCT02404935

Find a site near you

Start Over

H pital Saint Gregoire

Saint Gregoire, France
  Connect »

Gustave Roussy

Villejuif, France
  Connect »

Clinique du Cap d'Or

La Seyne-sur-Mer, France
  Connect »

H pital Bic tre

Le Kremlin Bicêtre, France
  Connect »

CHU Saint Etienne - H pital Nord

Saint-Priest-en-Jarez, France
  Connect »

H pital Bic tre

Le Kremlin Bicêtre, France
  Connect »